Sales 2024 * | 72.54M 99.08M | Sales 2025 * | 68.35M 93.35M | Capitalization | 242M 331M |
---|---|---|---|---|---|
Net income 2024 * | -168M -229M | Net income 2025 * | -167M -228M | EV / Sales 2024 * | 1.76 x |
Net cash position 2024 * | 115M 157M | Net cash position 2025 * | 281M 384M | EV / Sales 2025 * | -0.57 x |
P/E ratio 2024 * |
-1.56
x | P/E ratio 2025 * |
-1.97
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.18% |
Latest transcript on Nektar Therapeutics
Managers | Title | Age | Since |
---|---|---|---|
Howard Robin
CEO | Chief Executive Officer | 71 | 06-12-31 |
Robert Chess
CHM | Chairman | 66 | 91-11-30 |
Sandra Gardiner
DFI | Director of Finance/CFO | 58 | 23-04-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
R. Scott Greer
BRD | Director/Board Member | 65 | 09-12-31 |
Roy A. Whitfield
BRD | Director/Board Member | 70 | 00-07-31 |
Robert Chess
CHM | Chairman | 66 | 91-11-30 |
1st Jan change | Capi. | |
---|---|---|
+25.83% | 661B | |
+27.35% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+14.45% | 231B | |
+4.54% | 200B | |
-9.37% | 195B | |
-6.26% | 145B |